Protein kinases (PKs), one of the largest protein families, can be further divided into different
groups based on their substrate or structure and function. PKs are important signaling …

Metabolic dysfunction-associated steatotic liver disease (MASLD) comprises a spectrum of
liver diseases that span simple steatosis, metabolic dysfunction-associated steatohepatitis …

Background and aim Sodium-glucose co-transporter 2 inhibitors (SGLT2i) has been verified
to improve Non-alcoholic fatty liver disease (NAFLD) in previous clinical practice. We mainly …

Background The estimated global prevalence and burden of non‐alcoholic fatty liver
disease (NAFLD) and its advanced stage, non‐alcoholic steatohepatitis (NASH), is …

Metabolic-associated Fatty Liver Disease is one of the outstanding challenges in
gastroenterology. The increasing incidence of the disease is undoubtedly connected with …

Since there are currently no US Food and Drug Administration (FDA)-approved drugs for the
treatment of non-alcoholic steatohepatitis (NASH), various NASH treatments are under …

The pathogenesis of non-alcoholic steatohepatitis (NASH) involves the simultaneous
interaction of multiple factors such as lipid accumulation, oxidative stress, and inflammatory …

Oxidative stress is key in type 2 diabetes-associated nonalcoholic fatty liver disease
(NAFLD). We explored whether extracellular superoxide dismutase (EC-SOD) activates …

Simple Summary The effects of thiazolidinedione (TZD) on multiple myeloma have not been
investigated in humans. The reimbursement database of Taiwan's National Health …

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease
worldwide, and its incidence and related complications are expected to rise with the global …